Travatan Z: adverse event reports filed with FDA

3,937

reports as suspect product

0% of all reports · about 205 a year

108

reports, 12 months to June 2026

39 in the 12 months before

22.3%

marked serious by the reporter

27.8% across the class

2.1%

record death among outcomes, as reported

84 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Travatan Z reports recording the termmedian drug in prostaglandin analog

1. Treatment failurethe treatment did not work29.5%1,160
2. Ocular hyperaemiaa red eye9.3%365
3. Eye irritationeye irritation8.2%324
4. Drug ineffectivethe medicine did not work as expected6.6%260
5. Eye paineye pain5.4%212
6. Intraocular pressure increasedraised pressure in the eye4.9%192
7. Glaucomaraised pressure in the eye4.7%186
8. Hypersensitivityan allergic-type reaction4%158
9. Visual impairmentreduced vision3.7%145
10. Vision blurredblurred vision2.9%114
11. Dry eyedry eye2.3%92
12. Eye pruritus2.3%91
13. Blindnessloss of sight2.1%83
14. Hypoacusisreduced hearing1.8%71
15. Deaththe patient died; cause not stated by this term1.6%64
16. Headachehead pain1.6%64
17. Malaisegeneral feeling of being unwell1.6%62
18. Product quality issuea problem with the product itself1.5%58
19. Eye disorder1.4%56
20. Circumstance or information capable of leading to medication errora situation that could lead to a medication error1.3%53
21. Product packaging quantity issue1.3%50
22. Cataractclouding of the eye lens1.2%49
23. Expired product administeredthe product was used past its expiry date1.2%48
24. Blindness unilateral1.2%46
25. Drug hypersensitivityan allergic-type reaction to a medicine1.1%44
26. No adverse eventno adverse event was reported1.1%43
27. Product container seal issue1.1%42
28. Dizzinesslight-headedness or unsteadiness1%41
29. Ocular discomfort1%41
30. Product dropper issue1%39

Top 30 of 305 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 13 drugs in the prostaglandin analog class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 51,210 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 95.2% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 3,937 reports.

Drugs most often listed in the same reports

Other products listed in reports where Travatan Z is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the prostaglandin analog class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Travatan Z as a suspect or interacting product; reports listing it only as a concomitant medication (1,703) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.